Clinical Trials Logo

Clinical Trial Summary

Atni-HBs to HBsAg and Anit-HBc was interpreted based on three hepatitis markers for clinical detection of HBV-infections. HBAg and Anti-HBs were negative and the Anit-HBc-positive referred to as Anti-HBc alone. When the Anti-HBc alone occurs, patients may be due to mutations in HBV HBsAg can not be detected due to (1), but if by the molecular diagnostics by polymerase chain reaction (PCR) technology can detect HBV DNA present. When Anti-HBc alone in patients with serum HBV DNA can be measured, then there may be occult HBV infection. In different countries, Occult HBV infection in the Anti-HBc Alone group had significant differences in the prevalence (2.9 ~ 22.8%) (2), but prevalence survey in Taiwan there are very few studies on this , It is hoped to be able to investigation the prevalence of occult HBV infection Among Anti-HBc Alone.


Clinical Trial Description

The main use of this program, Taipei Medical University - Wan Fang Hospital in clinical specimens using the Roche system (Corbas e601) operating HBsAg, Anti-HBs, Anti-HBc to screen for the Anti-HBc alone group. Recycling Roche molecular system (Taq48) Real-time PCR to detect all anti-HBc alone population to understand their serum HBV-DNA viral load, in order to understand Occult HBV infection in the Anti-HBc alone group, the prevalence and viral load changes in these studies through the clinical units to provide occult HBV infection as a reference basis. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01396538
Study type Observational
Source Taipei Medical University WanFang Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date June 2011
Completion date May 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03645044 - Towards a Functional Cure for HBV - The COMMIT Cohort Study
Not yet recruiting NCT06338826 - Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses Phase 2
Not yet recruiting NCT01318096 - Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients N/A
Active, not recruiting NCT04032860 - RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection Phase 4
Completed NCT02555943 - DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) Phase 2/Phase 3